ALK

Anaplastic lymphoma kinase; ALK tyrosine kinase receptor; CD246; Cluster of differentiation 246

Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor superfamily, is predominantly expressed in the brain and implicated in neuronal development and cognition. ALK catalyzes the transference of a gamma-phosphate group from adenosine triphosphate (ATP) to a tyrosine residue on a substrate protein. Therefore, it catalyzes a tyrosine residue phosphorylation reaction on its substrate proteins. The phosphorylation and dephosphorylation of proteins are critical reactions catalyzed by different enzymes (kinases and phosphatases), which play critical roles in various cellular functions.

ALK gene activation is involved in the carcinogenesis process of several human cancers such as anaplastic large cell lymphoma, lung cancer, inflammatory myofibroblastic tumors and neuroblastoma, as a consequence of fusion with other oncogenes (NPM, EML4, TIM, etc) or gene amplification, mutation or protein overexpression. ALK is a transmembrane tyrosine kinase receptor that, upon ligand binding to its extracellular domain, undergoes dimerization and subsequent autophosphorylation of the intracellular kinase domain. When activated in cancer it represents a target for specific inhibitors, such as Crizotinib, Ceritinib, Alectinib etc. which use has demonstrated significant effectiveness in ALK-positive non-small cell lung cancer particularly.

ALK Inhibitors

2-Keto Crizotinib
(PF-06260182) Cat. No.: HY-13320

2-Keto Crizotinib (PF-06260182) is an active lactam metabolite of crizotinib.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

6-Demethoxytangeretin
Cat. No.: HY-N4126

6-Demethoxytangeretin is a citrus flavonoid isolated from Citrus depressa.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Alectinib
(CH5424802; RO5424802; AF802) Cat. No.: HY-13011

Alectinib (CH5424802) is a potent, selective, and orally available **ALK** inhibitor with an IC_{50} of 1.9 nM and a K_d value of 2.4 nM (in an ATP-competitive manner), and also inhibits **ALK F1174L** and **ALK R1275Q** with IC_{50}s of 1 nM and 3.5 nM, respectively.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Alectinib Hydrochloride (CH5424802 Hydrochloride; RO5424802 Hydrochloride; AF-802 Hydrochloride)
Cat. No.: HY-13011A

Alectinib Hydrochloride (CH5424802 Hydrochloride; RO5424802 Hydrochloride; AF-802 Hydrochloride) is a potent, selective, and orally available **ALK** inhibitor with an IC_{50} of 1.9 nM and a K_d value of 2.4 nM (in an ATP-competitive manner), and also inhibits **ALK F1174L** and **ALK R1275Q** with...



Purity: 99.89%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Alectinib-d6
(CH5424802-d6; RO5424802-d6; AF802-d6) Cat. No.: HY-13011S1

Alectinib-d6 is deuterium labeled Alectinib.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Alectinib-d8
(CH5424802-d8; RO5424802-d8; AF802-d8) Cat. No.: HY-13011S

Alectinib-d8 (CH5424802-d8) is the deuterium labeled Alectinib.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ALK inhibitor 1
Cat. No.: HY-15357

ALK inhibitor 1 (compound 17) is a potent pyrimidin **ALK** inhibitor. ALK inhibitor 1 is a potent inhibitor of **testis-specific serine/threonine kinase 2** (**TSSK2**; IC_{50}=31 nM) and **focal adhesion kinase** (**FAK**; IC_{50}=2 nM).



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

ALK inhibitor 2
Cat. No.: HY-15358

ALK inhibitor 2 (compound 18) is a potent pyrimidin **ALK** inhibitor. ALK inhibitor 2 is a potent inhibitor of **testis-specific serine/threonine kinase 2** (**TSSK2**; IC_{50}=37 nM) and **focal adhesion kinase** (**FAK**; IC_{50}=5 nM).



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

ALK kinase inhibitor-1
Cat. No.: HY-19990

ALK kinase inhibitor-1 is an **anaplastic lymphoma kinase (ALK)** inhibitor extracted from patent US20130261106A1 compound I-202.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

ALK-IN-1
(Brigatinib analog) Cat. No.: HY-13464

ALK-IN-1 (Brigatinib analog) is a potent and selective active inhibitor of **anaplastic lymphoma kinase(ALK)**, Patent US20140066406 A1.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ALK-IN-12

Cat. No.: HY-108230

ALK-IN-12 is a potent and orally active **ALK** inhibitor with an **IC_{50}** of 0.18 nM. ALK-IN-12 also inhibits IGF1R and InsR (IC_{50}=20.3 and 90.6 nM). Antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ALK-IN-13

Cat. No.: HY-12973

ALK-IN-13 is an ALK inhibitor, extracted from patent US20130225528A1, example 19.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ALK-IN-5

Cat. No.: HY-128569

ALK-IN-5 is a potent, selective, and brain-penetrant inhibitor of **anaplastic lymphoma kinase (ALK)**, with an **IC_{50}** of 2.9 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ALK-IN-6

Cat. No.: HY-128596

ALK-IN-6 (compound 11) is an orally bioavailable inhibitor of **anaplastic lymphoma kinase (ALK)**, with **IC_{50}** values of 71 nM, 18.72 nM and 36.81 nM for ALK wild, ALK F1196M and ALK F1174L, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ALK-IN-9

Cat. No.: HY-131244

ALK-IN-9 (compound 40) is a potent **ALK** inhibitor. ALK-IN-9 inhibits cell proliferation with IC_{50}s of <0.2 nM, <0.2 nM, 0.2 nM for Ba/F3-EML4-ALK, KM 12 (TPM3-TRKA), KG-I cell (OP2-FGFR1), respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ALK/ROS1-IN-1

Cat. No.: HY-130794

ALK/ROS1-IN-1 (compound 2e) is a potent and selective anti crizotinib-resistant **ALK/ROS1** dual inhibitor, with **IC_{50}**s of 0.174 μM and 0.530 μM for ALK and ROS1 enzyme, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ALK5-IN-6

Cat. No.: HY-142950

ALK5-IN-6 is a potent inhibitor of **ALK5**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ALK5-IN-7

Cat. No.: HY-142949

ALK5-IN-7 is a potent inhibitor of **ALK5**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ASP3026

Cat. No.: HY-13326

ASP3026 is a potent, selective and orally active inhibitor of **anaplastic lymphoma kinase (ALK)**. ASP3026 induces apoptosis of tumor cells. ASP3026 can be used for the research of non-small cell lung cancer (NSCLC).



Purity: 99.90%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 50 mg, 100 mg

AZD-3463

(ALK/IGF1R inhibitor)

Cat. No.: HY-15609

AZD-3463 (ALK/IGF1R inhibitor) is an orally active **ALK/IGF1R** inhibitor, with a **K_i** of 0.75 nM for ALK. AZD3463 induces **apoptosis** and **autophagy** in neuroblastoma cells.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Belizatinib

(TSR-011) Cat. No.: HY-17603

Belizatinib is an oral, dual, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with IC_{50} of 0.7nM for wild-type recombinant ALK kinase.



Purity: 99.66%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Brigatinib

(AP-26113) Cat. No.: HY-12857

Brigatinib (AP-26113) is a highly potent and selective **ALK** inhibitor, with an IC_{50} of 0.6 nM.



Purity: 99.98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Brigatinib-13C6

(AP-26113-13C6) Cat. No.: HY-12857S

Brigatinib-13C6 (AP-26113-13C6) is the 13C-labeled Brigatinib. Brigatinib (AP-26113) is a highly potent and selective **ALK** inhibitor, with an IC_{50} of 0.6 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Brigatinib-d3

(AP-26113-d3) Cat. No.: HY-12857S1

Brigatinib-d3 (AP-26113-d3) is the deuterium labeled Brigatinib. Brigatinib (AP-26113) is a highly potent and selective **ALK** inhibitor, with an IC_{50} of 0.6 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CEP-28122

Cat. No.: HY-18030

CEP-28122 is a highly potent and selective orally active ALK inhibitor with IC50 of 1.9 ± 0.5 nM in an enzyme-based TRF assay. IC50 value: 1.9 ± 0.5 nM Target: ALK in vitro: CEP-28122 is a potent inhibitor of recombinant ALK activity and cellular ALK tyrosine phosphorylation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CEP-28122 mesylate salt

Cat. No.: HY-18030A

CEP-28122 mesylate salt, a diaminopyrimidine derivative, is a potent, selective, and orally bioavailable **ALK** inhibitor, with an IC_{50} value of 1.9 nM for recombinant ALK kinase activity. CEP-28122 has antitumor activity in experimental models of ALK-positive human cancers.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CEP-37440

Cat. No.: HY-15841

CEP-37440 is a novel potent and selective Dual FAK/ALK inhibitor with IC50 s of 2.3 nM (FAK) and 120 nM(ALK cellular IC50 in 75% human plasma).



Purity: 99.97%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ceritinib

(LDK378) Cat. No.: HY-15656

Ceritinib (LDK378) is a selective, orally bioavailable, and ATP-competitive **ALK** tyrosine kinase inhibitor with an IC_{50} of 200 pM. Ceritinib (LDK378) also inhibits **IGF-1R**, **InsR**, and **STK22D** with IC_{50} values of 8, 7, and 23 nM, respectively. Ceritinib (LDK378) shows great antitumor potency.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Ceritinib D7

(LDK378 D7) Cat. No.: HY-15656S

Ceritinib D7 (LDK378 D7) is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ceritinib dihydrochloride

(LDK378 dihydrochloride) Cat. No.: HY-15656A

Ceritinib dihydrochloride (LDK378 dihydrochloride) is a selective, orally bioavailable and ATP-competitive **ALK** tyrosine kinase inhibitor with an IC_{50} of 200 pM.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CJ-2360

Cat. No.: HY-131909

CJ-2360 is a potent and orally active **ALK** inhibitor with **IC_{50}**s of 2.2, 4.0, 8.8, 6.3, and 8.9 nM against wild-type ALK and F1197M, G1269A, L1196M, and S1206Y ALK mutants, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Con B-1

Cat. No.: HY-142287

ConB-1 is a potent and selective **ALK** inhibitor with low toxicity to normal cells.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

Crizotinib

(PF-02341066)

Cat. No.: HY-50878

Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive **ALK** and **c-Met** inhibitor with **IC_{50}**s of 20 and 8 nM, respectively.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Crizotinib hydrochloride

(PF-02341066 hydrochloride)

Cat. No.: HY-50878A

Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual **ALK** and **c-Met** inhibitor with **IC_{50}**s of 20 and 8 nM, respectively.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Crizotinib-d5

(PF-02341066-d5)

Cat. No.: HY-50878S

Crizotinib-d5 (PF-02341066-d5) is the deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive **ALK** and **c-Met** inhibitor with **IC_{50}**s of 20 and 8 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EML4-ALK kinase inhibitor 1

Cat. No.: HY-111752

EML4-ALK kinase inhibitor 1 is a potent orally active inhibitor of echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase **(EML4-ALK)**, with an **IC_{50}** of 1 nM.



Purity: 98.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ensartinib

(X-396)

Cat. No.: HY-103714

Ensartinib (X-396) is a potent and dual **ALK/MET** inhibitor with **IC_{50}**s of <0.4 nM and 0.74 nM, respectively.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Ensartinib dihydrochloride

(X-396 dihydrochloride)

Cat. No.: HY-103714A

Ensartinib dihydrochloride (X-396 dihydrochloride) is a potent and dual **ALK/MET** inhibitor with **IC_{50}**s of <0.4 nM and 0.74 nM, respectively.



Purity: 99.46%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Entrectinib

(NMS-E628; RXDX-101)

Cat. No.: HY-12678

Entrectinib (NMS-E628) is a potent, orally available, and CNS-active **pan-Trk**, **ROS1**, and **ALK** inhibitor. Entrectinib inhibits TrkA, TrkB, TrkC, ROS1 and ALK with **IC_{50}** values of 1, 3, 5, 12 and 7 nM, respectively. Antitumor activity.



Purity: 99.32%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Envonalkib

Cat. No.: HY-145566

Envonalkib is a potent and orally active inhibitor of **ALK**, with **IC_{50}**s of 1.96 nM, 35.1 nM, and 61.3 nM for **WT** and **mutated L1196M** and **G1269S-ALK**. Envonalkib can be used for the research of non-small cell lung cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

F-1

Cat. No.: HY-112801

F-1 is a potent **ALK** and **ROS1** dual inhibitor, suppresses phospho-ALK and its relative downstream signaling pathways, with IC_{50}s of 2.1 nM, 2.3 nM, 1.3 nM and 3.9 nM for ALK^{WT}, $ROS1^{WT}$, ALK^{L1196M} and ALK^{G1202R}, respectively.



Purity: 98.65%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

GSK1838705A

Cat. No.: HY-13020

GSK1838705A is a potent and reversible **IGF-IR** and the **insulin receptor** inhibitor with IC_{50}s of 2.0 and 1.6 nM, respectively. It also inhibits **ALK** with an IC_{50} of 0.5 nM.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

HG-14-10-04

Cat. No.: HY-15801

HG-14-10-04 (example 10) is a potent and specific **ALK** inhibitor with an IC_{50} of 20 nM.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Iruplinalkib

(WX-0593)

Cat. No.: HY-145574

Iruplinalkib (WX-0593) is a potent, selective, and orally active inhibitor of **ALK** and **ROS1** tyrosine kinase. Iruplinalkib (WX-0593) shows favorable safety and promising antitumor activity in advanced NSCLC with ALK or ROS1 rearrangement.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Itacnosertib

(TP-0184)

Cat. No.: HY-109179

Itacnosertib (TP-0184) is both inhibitor to **JAK2**, **ACVR1 (ALK2)** and **ALK5** as described in WO2014151871.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

J-1063

Cat. No.: HY-145855

J-1063 is a potent, selective and orally active **ALK5** inhibitor with an IC_{50} of 0.039 μM. J-1063 shows anti-fibrotic effect by the inhibition of inflammatory infiltration, collagen deposition, and hepatocytes necrosis. J-1063 has the potential for the research of liver fibrosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JH-VIII-157-02

Cat. No.: HY-112140

JH-VIII-157-02 is a structural analogue of alectinib, acts as an **ALK** inhibitor, and shows an IC_{50} of 2 nM for echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK) G1202R in cells.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

KRCA-0008

Cat. No.: HY-12331

KRCA-0008 is a potent and selective ALK/Ack1 inhibitor with IC50 of 12 nM/4 nM for ALK and Ack1 respectively; displays drug-like properties without hERG liability.



Purity: 98.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lorlatinib

(PF-06463922)

Cat. No.: HY-12215

Lorlatinib (PF-06463922) is a selective, orally active, brain-penetrant and ATP-competitive **ROS1/ALK** inhibitor. Lorlatinib has K_is of <0.025 nM, <0.07 nM, and 0.7 nM for ROS1, wild type ALK, and ALK^{L1196M}, respectively. Lorlatinib has anticancer activity.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lorlatinib-13C,d3

(PF-06463922-13C,d3)

Cat. No.: HY-12215S

Lorlatinib-13C,d3 (PF-06463922-13C,d3) is the 13C- and deuterium labeled Lorlatinib. Lorlatinib (PF-06463922) is a selective, orally active, brain-penetrant and ATP-competitive **ROS1/ALK** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MS4077

Cat. No.: HY-112156

MS4077 is an anaplastic lymphoma kinase (**ALK**) **PROTAC** (degrader) based on **Cereblon** ligand, with a K_d of 37 nM for binding affinity to ALK.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

MS4078

Cat. No.: HY-112155

MS4078 is an anaplastic lymphoma kinase (**ALK**) **PROTAC** (degrader) based on **Cereblon** ligand, with a K_d of 19 nM for binding affinity to ALK.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NVP-TAE 684

(TAE 684)

Cat. No.: HY-10192

NVP-TAE 684 (TAE 684) is a highly potent and selective **ALK** inhibitor, which blocks the growth of ALCL-derived and ALK-dependent cell lines with IC_{50} values between 2 and 10 nM.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Repotrectinib

(TPX-0005)

Cat. No.: HY-103022

Repotrectinib (TPX-0005) is a potent **ROS1** (IC_{50}=0.07 nM) and **TRK** (IC_{50}=0.83/0.05/0.1 nM for TRKA/B/C) inhibitor. Repotrectinib potently inhibits WT **ALK** (IC_{50}=1.01 nM). Repotrectinib has anti-cancer activity.



Purity: 99.81%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

RIPK2-IN-1

Cat. No.: HY-146694

RIPK2-IN-1 (compound 18f) is a potent **RIPK2** inhibitor with an IC_{50} of 51 nM. RIPK2-IN-1 inhibits **ALK2** with an IC_{50} of 5 nM. RIPK2-IN-1 has an IC_{50} of 390 nM on RIPK2/NOD2 in cell assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SIAIS117

Cat. No.: HY-146022

SIAIS117 is a potent **Brigatinib-PROTAC** degrader. SIAIS117 is a **ALK PROTAC** based on Brigatinib and VHL-1 conjunction. SIAIS117 can degrade **ALK G1202R** point mutation effectively. SIAIS117 blocks the growth of SR and H2228 cancer cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TL13-110

Cat. No.: HY-136195

TL13-110 is a negative control for TL13-112 (HY-123919) and a potent ALK inhibitor with an IC_{50} of 0.34 nM. TL13-110 does not degrade **ALK** in cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TL13-112

Cat. No.: HY-123919

TL13-112 is a potent and selective **ALK-PROTAC** degrader and inhibits **ALK** activity with an IC_{50} value of 0.14 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TL13-12

Cat. No.: HY-122582

TL13-12 is a potent and selective **ALK-PROTAC** degrader and inhibits **ALK** activity with an IC_{50} value of 0.69 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TL13-22

Cat. No.: HY-136194

TL13-22 is a negative control for TL13-12 (HY-122582) and a potent **ALK** inhibitor with an IC_{50} of 0.54 nM. TL13-22 does not degrade **ALK** in cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TP-008

Cat. No.: HY-125851

TP-008 is a potent, selective and orally active **(Activin-Like Kinase 5) ALK5** inhibitor with **pIC_{50}** and **pEC_{50}** values of 7.6 and 6.63, respectively. TGFβRI-IN-2 can produce observed cardiac toxicity in vivo at high dose.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TPX-0131

Cat. No.: HY-139279

TPX-0131 is a potent, selective, CNS-penetrant and orally active inhibitor of **wild-type ALK** (IC_{50} of 1.4 nM) and **ALK-resistant mutation**, e.g. **G1202R** (IC_{50} of 0.3 nM), **L1196M** (IC_{50} of 0.3 nM). TPX-0131 has strong antitumor activities.



Purity: ≥95.0%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg

TRK/ALK-IN-1

Cat. No.: HY-144732

TRK/ALK-IN-1 (compound 21) is a potent and dual inhibitor of **TRK** and **ALK**. TRK/ALK-IN-1 in the enzymatic assays is in good accordance with anti-proliferative activity with **IC_{50}** values of 2.2, 9.3 and 38 nM towards TRKA, ALK^{WT} and ALK^{L1196M}, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

UNC5293

Cat. No.: HY-132200

UNC5293 is a **MERTK**-selective and potent inhibitor (K_i=190 pM). UNC5293 inhibits MERTK (IC_{50}=0.9 nM) and is more selective over Axl, Tyro3 and Flt3. UNC5293 exhibits excellent mouse PK properties and is used for bone marrow leukemia research.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

WY-135

Cat. No.: HY-111416

WY-135 is an **ALK** (IC_{50}=1.4 nM) and **ROS1** (IC_{50}=1.1 nM) dual inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

X-376

Cat. No.: HY-16590

X-376 is a potent and highly specific **ALK** tyrosine kinase inhibitor (TKI) (IC_{50}=0.61 nM). X-376 is a less potent inhibitor of **MET** (IC_{50}=0.69 nM). X-376 displays potent anti-tumor activity.



Purity: 98.36%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

XST-14

Cat. No.: HY-137506

XST-14 is a potent, competitive and highly selective **ULK1** inhibitor with an **IC_{50}** of 26.6 nM. XST-14 induces **autophagy** inhibition by reducing the phosphorylation of the ULK1 downstream substrate.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Zilurgisertib

Cat. No.: HY-145608

Zilurgisertib is a selective **ALK 2** inhibitor for treating diseases such as cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZX-29

Cat. No.: HY-135887

ZX-29 is a potent and selective **ALK** inhibitor with an **IC_{50}** of 2.1 nM, 1.3 nM and 3.9 nM for **ALK**, **ALK L1196M** and **ALK G1202R** mutations, respectively. ZX-29 is inactive against EGFR.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg